Pharmacokinetics of low molecular weight heparin and unfractionated heparin in pregnancy

Journal of the Society for Gynecologic Investigation

Volumn 11, Issue 6, 2004, Pages 377-383

  Ensom, Mary H H ^a,b   Stephenson, Mary D ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OB7   (Canada)

Author keywords

Antiphospholipid antibody syndrome; dalteparin; pharmacokinetics; pregnancy; unfractionated heparin

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 10A ANTIBODY; DALTEPARIN; HEPARIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CESAREAN SECTION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; ERYTHROCYTE CONCENTRATE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INTRAUTERINE GROWTH RETARDATION; MATERNAL PLASMA; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; VAGINAL DELIVERY; VULVA DISEASE; VULVAR HEMATOMA;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTERS;

EID: 4444279681     PISSN: 10715576     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsgi.2004.02.007     Document Type: Article

References (24)

1. B.A. Duplaga, C.W. Rivers, E. Nutescu Dosing and monitoring of low-molecular-weight heparins in special populations Pharmacotherapy 21 2001 218 234
2. A. Eldor The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy Eur J Obstet Gynecol Reprod Biol 104 2002 3 13
3. M.H.H. Ensom, M.D. Stephenson Low-molecular-weight heparins in pregnancy Pharmacotherapy 19 1999 1013 1025
4. M. Backos, R. Rai, N. Baxter, I.T. Chilcott, H. Cohen, L. Regan Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin Br J Obstet Gynaecol 106 1999 102 107
5. D.A. Triplett Antiphospholipid antibodies proposed mechanisms of action Am J Reprod Immunol 28 1992 211 215
6. R.R. Adler, A.K. Ng, N.S. Rote Monoclonal antiphosphatidylserine antibody inhibits intercellular fusion of the choriocarcinoma line, JAR Biol Reprod 53 1995 905 910
7. H. Katsuragawa, H. Kanzaki, T. Inoue, T. Hirano, T. Mori, N.S. Rote Monoclonal antibody against phosphatidylserine inhibits in vitro human trophoblastic hormone production and invasion Biol Reprod 56 1997 50 58
8. R. Rai, H. Cohen, M. Dave, L. Regan Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies) BMJ 314 1997 253 257
9. W.H. Kutteh Antiphospholipid antibody-associated recurrent pregnancy loss Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone Am J Obstet Gynecol 174 1996 1584 1589
10. W.A. Wilson, A.E. Gharavi, T. Koike International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome Report of an international workshop Arthritis Rheum 42 1999 1309 1311
11. Antiphospholipid syndrome ACOG Educational Bulletin 244 1998 151 158
12. A.N. Teien, M. Lie Evaluation of an amidolytic heparin assay method Increased sensitivity by adding purified antithrombin III Thromb Res 10 1977 399 410
13. R.J. Kandrotas Heparin pharmacokinetics and pharmacodynamics Clin Pharmacokinet 22 1992 359 374
14. H.L. Casele, S.A. Laifer, D.A. Woelkers, R. Venkataramanan Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy Am J Obstet Gynecol 181 1999 1113 1117
15. M. Blomback, K. Bremme, M. Hellgren, H. Lindberg A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy Blood Coagul Fibrinolysis 9 1998 343 350
16. V. Pettila, R. Kaaja, P. Leinonen, U. Ekblad, M. Kataja, E. Ikkala Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy Thromb Res 96 1999 275 282
17. V. Sephton, R.G. Farquharson, J. Topping A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy Obstet Gynecol 101 2003 1307 1311
18. J.E. Brennand, I.D. Walker, I.A. Greer Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin Acta Haematol 101 1999 53 55
19. M.A. Crowther, K. Spitzer, J. Julian Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study Thromb Res 98 2000 133 138
20. L.R. Whitfield, A.S. Lele, G. Levy Effect of pregnancy on the relationship between concentration and anticoagulant action of heparin Clin Pharmacol Ther 34 1983 23 28
21. T.C. Dahlman, M.S. Hellgren, M. Blomback Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma Am J Obstet Gynecol 161 1989 420 425
22. L.R. Brancazio, K.A. Roperti, R. Stierer, S.A. Laifer Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy Am J Obstet Gynecol 173 1995 1240 1245
23. L.A. Barbour, J.M. Smith, R.A. Marlar Heparin levels to guide thromboembolism prophylaxis during pregnancy Am J Obstet Gynecol 173 1995 1869 1873
24. D. Rosenbloom, J.S. Ginsbery Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy Can J Hosp Pharm 55 2002 15 19